Acceptability and feasibility of pre-exposure prophylaxis for bacterial STIs: a systematic review.

Julie-Anne Carroll, Amy B Mullens, Sarah Warzywoda, Philip R A Baker, Meika Stafford, Faye McMillan, Jacintha Manton, Daniel Demant
Author Information
  1. Julie-Anne Carroll: School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia. ORCID
  2. Amy B Mullens: School of Psychology and Wellbeing, Centre for Health Research, Institute for Resilient Regions, University of Southern Queensland, Ipswich, Queensland, Australia. ORCID
  3. Sarah Warzywoda: School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  4. Philip R A Baker: School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia. ORCID
  5. Meika Stafford: School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.
  6. Faye McMillan: School of Public Health, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia.
  7. Jacintha Manton: School of Public Health, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia.
  8. Daniel Demant: School of Public Health, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia. ORCID

Abstract

BACKGROUND: A recent resurgence of bacterial sexually transmitted infections (STIs) is placing a major burden on high-risk populations, physicians, and the healthcare system. Treatment in the form of antibiotic pre-exposure prophylaxis (STI PrEP) is a potential solution. However, little is known about the acceptability and feasibility of this approach in high-risk populations.
METHODS: A comprehensive search strategy was developed and executed in October 2024 across six databases adhering to PRISMA guidelines.
RESULTS: Eight studies met the inclusion criteria. These studies were all conducted in high-income countries, used various methods, and all focussed on sexual minority men. Findings consistently identified moderate to high levels of acceptability among GBMSM (54.3% - 67.5%). Factors such as engagement in perceived 'high risk' sexual encounters, and past diagnosis of STIs strengthened acceptability, while others (e.g., antimicrobial resistance concerns and stigma) act as barriers. Only one study included the perspectives of healthcare workers, indicating a moderate willingness to prescribe, which would increase under governing-body endorsement.
DISCUSSION: Overall, while there is some promise of STI PrEP acceptability among GBMSM, vast gaps in knowledge remain. Knowledge transfer and feasibility and, hence, the sustainability and capacity needed for the success of STI PrEP is yet to be examined and understood. However, for STI PrEP to be successfully adopted, it is essential not only to assess its acceptability and feasibility but also to focus on knowledge transfer. Knowledge transfer is a dynamic and iterative process, involving the synthesis, dissemination, exchange, and application of knowledge in an ethically sound manner. This process supports the improvement of health outcomes, strengthens healthcare systems, and ensures that healthcare interventions, such as STI PrEP, are effectively understood and implemented by both healthcare providers and at-risk populations. Similarly, the perspectives of populations beyond GBMSM have been omitted, and there is little understanding of the impact of their differing socio-cultural contexts around sex-related behaviour and Western pharmaceutical healthcare interventions on their acceptance and uptake.
CONCLUSION: Further research into acceptability, feasibility and knowledge transfer among diverse high-risk groups, healthcare professionals, and policymakers is necessary to create a strong foundation for implementing STI PrEP.

References

  1. Sex Health. 2021 Sep;18(4):346-348 [PMID: 34412769]
  2. Front Med (Lausanne). 2022 Sep 20;9:952476 [PMID: 36203757]
  3. J Sex Res. 2019 Jan;56(1):1-8 [PMID: 30044926]
  4. Cult Health Sex. 2024 Jul;26(7):936-951 [PMID: 37950430]
  5. Health Psychol Open. 2015 Apr 30;2(1):2055102915581562 [PMID: 28070355]
  6. BMC Public Health. 2022 Oct 15;22(1):1926 [PMID: 36243692]
  7. BMC Public Health. 2023 Mar 16;23(1):505 [PMID: 36922801]
  8. Curr HIV/AIDS Rep. 2021 Aug;18(4):280-288 [PMID: 34091858]
  9. Clin Infect Dis. 2020 Mar 3;70(6):1247-1253 [PMID: 31504345]
  10. Open Access J Contracept. 2018 Nov 12;9:91-112 [PMID: 30519127]
  11. Subst Use Misuse. 2017 Jul 3;52(8):1027-1038 [PMID: 28318357]
  12. MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9 [PMID: 22874836]
  13. Int J Environ Res Public Health. 2023 Feb 28;20(5): [PMID: 36901357]
  14. Sex Transm Dis. 2001 Oct;28(10):579-97 [PMID: 11689757]
  15. AIDS Behav. 2024 Jan;28(1):125-134 [PMID: 37474623]
  16. Sex Reprod Healthc. 2020 Oct;25:100534 [PMID: 32512536]
  17. Sex Health. 2020 Apr;17(2):129-134 [PMID: 32213272]
  18. Res Nurs Health. 2008 Feb;31(1):1-3 [PMID: 18183570]
  19. Int J Transgend. 2018 Nov 22;20(1):4-20 [PMID: 32999591]
  20. Cult Health Sex. 2024 Jun;26(6):790-807 [PMID: 37755697]
  21. PLoS One. 2022 Oct 19;17(10):e0276209 [PMID: 36260550]
  22. Int J Equity Health. 2018 May 21;17(1):62 [PMID: 29784050]
  23. Sex Transm Dis. 2011 Jul;38(7):573-9 [PMID: 21343845]
  24. Sex Transm Dis. 2020 Apr;47(4):224-231 [PMID: 31977974]
  25. Sex Transm Dis. 2021 Sep 1;48(9):615-619 [PMID: 33560092]
  26. BMC Health Serv Res. 2019 Feb 2;19(1):93 [PMID: 30711001]
  27. J Antimicrob Chemother. 2023 Jul 5;78(7):1561-1568 [PMID: 37129293]
  28. Sex Health. 2023 Aug;20(4):282-295 [PMID: 37603534]
  29. J Eval Clin Pract. 2018 Jun;24(3):459-467 [PMID: 29464873]
  30. Sex Transm Infect. 2010 Jun;86(3):163-8 [PMID: 19854700]
  31. AIDS Behav. 2021 Aug;25(8):2657-2660 [PMID: 33745099]
  32. Curr Opin Infect Dis. 2020 Feb;33(1):51-58 [PMID: 31789694]
  33. J Community Health. 2020 Feb;45(1):201-218 [PMID: 31332639]
  34. Sociol Health Illn. 2019 Nov;41(8):1535-1548 [PMID: 31215066]
  35. BMC Health Serv Res. 2017 Jan 26;17(1):88 [PMID: 28126032]
  36. J Travel Med. 2024 Jun 3;31(4): [PMID: 38340322]
  37. J Pediatr Adolesc Gynecol. 2017 Jun;30(3):341-348 [PMID: 28167140]
  38. AIDS Care. 2021 Nov;33(11):1500-1506 [PMID: 32964738]
  39. BMJ Open. 2022 Jan 3;12(1):e057127 [PMID: 34980631]
  40. Sex Transm Dis. 2021 Sep 1;48(9):620-621 [PMID: 34117188]
  41. Int J STD AIDS. 2002 May;13(5):285-300 [PMID: 11972932]
  42. Am J Public Health. 2015 Mar;105(3):e88-94 [PMID: 25602881]
  43. AIDS. 2012 Feb 20;26(4):437-45 [PMID: 22095197]
  44. Health Aff (Millwood). 2022 Feb;41(2):281-288 [PMID: 35130067]
  45. BMJ Open. 2019 Nov 21;9(11):e031239 [PMID: 31753877]
  46. Am J Reprod Immunol. 2011 Mar;65(3):308-16 [PMID: 21214660]
  47. Sex Transm Dis. 2023 Mar 1;50(3):144-149 [PMID: 36730780]
  48. Sex Health. 2024 Jan;21: [PMID: 38219736]
  49. CMAJ. 2009 Aug 4;181(3-4):165-8 [PMID: 19620273]
  50. JBI Evid Synth. 2023 Nov 01;21(11):2247-2254 [PMID: 37232585]
  51. Int J Surg. 2021 Apr;88:105906 [PMID: 33789826]
  52. AIDS Behav. 2014 May;18(5):921-32 [PMID: 24569887]
  53. Addict Behav Rep. 2021 Dec 11;16:100399 [PMID: 35712328]
  54. Sex Health. 2021 Sep;18(4):294-302 [PMID: 34399883]
  55. Med J Aust. 2024 Apr 15;220(7):381-386 [PMID: 38479437]
  56. Bull World Health Organ. 2009 Nov;87(11):858-65 [PMID: 20072772]
  57. J Clin Aesthet Dermatol. 2020 Sep;13(9):26-32 [PMID: 33133338]
  58. BMC Public Health. 2023 May 10;23(1):847 [PMID: 37165347]

MeSH Term

Humans
Pre-Exposure Prophylaxis
Male
Sexually Transmitted Diseases, Bacterial
Patient Acceptance of Health Care
Sexual and Gender Minorities
Feasibility Studies
Anti-Bacterial Agents
Sexually Transmitted Diseases

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0healthcareSTIPrEPacceptabilityfeasibilitypopulationsknowledgetransferhigh-riskamongGBMSMbacterialSTIspre-exposureprophylaxisHoweverlittlestudiessexualmoderateperspectivesKnowledgeunderstoodprocessinterventionsBACKGROUND:recentresurgencesexuallytransmittedinfectionsplacingmajorburdenphysicianssystemTreatmentformantibioticpotentialsolutionknownapproachMETHODS:comprehensivesearchstrategydevelopedexecutedOctober2024acrosssixdatabasesadheringPRISMAguidelinesRESULTS:Eightmetinclusioncriteriaconductedhigh-incomecountriesusedvariousmethodsfocussedminoritymenFindingsconsistentlyidentifiedhighlevels543%-675%Factorsengagementperceived'highrisk'encounterspastdiagnosisstrengthenedothersegantimicrobialresistanceconcernsstigmaactbarriersonestudyincludedworkersindicatingwillingnessprescribeincreasegoverning-bodyendorsementDISCUSSION:Overallpromisevastgapsremainhencesustainabilitycapacityneededsuccessyetexaminedsuccessfullyadoptedessentialassessalsofocusdynamiciterativeinvolvingsynthesisdisseminationexchangeapplicationethicallysoundmannersupportsimprovementhealthoutcomesstrengthenssystemsensureseffectivelyimplementedprovidersat-riskSimilarlybeyondomittedunderstandingimpactdifferingsocio-culturalcontextsaroundsex-relatedbehaviourWesternpharmaceuticalacceptanceuptakeCONCLUSION:researchdiversegroupsprofessionalspolicymakersnecessarycreatestrongfoundationimplementingAcceptabilitySTIs:systematicreview

Similar Articles

Cited By